Silver Book

Silver Book Fact

Reduction of central-line infections saved ~ 1,800 lives and $280 million

Standardization of best practice interventions reduced central line-associated blood stream infections and saved an estimated 1,800 lives and $280 million.

Preventing Healthcare-Associated Infections: Initiating promising solutions and expanding proven ones: Commentaries by AHRQ Director, Dr. Carolyn Clancy, and other staff members. https://archive.ahrq.gov/news/newsroom/commentaries/preventing-healthcare-associated-infections.html. Published 2010

Reference

Title
Preventing Healthcare-Associated Infections: Initiating promising solutions and expanding proven ones: Commentaries by AHRQ Director, Dr. Carolyn Clancy, and other staff members
Publication Date
Published 2010
Authors
Agency for Healthcare Research and Quality
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value
  • Economic Value

Publications

Healthcare-Associated Infections Factsheet

 https://www.silverbook.org/wp-content/uploads/2015/06/Screen-Shot-2015-06-30-at-3.02.28-PM.png Thumbnail

Related Facts

  • An antibiotic stewardship program saved $17 million over 8 years
    An antibiotic stewardship program saved a total of $17 million over 8 years, with antibiotic costs rising $1 million in the first year after discontinuation.  
  • Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly
    Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.  
  • Reduction of central-line infections saved ~ 1,800 lives and $280 million
    Standardization of best practice interventions reduced central line-associated blood stream infections and saved an estimated 1,800 lives and $280 million.  
  • Reduction in hospital-acquired HAIs could produce significant savings
    Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up…  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.